the influence of autologous lymphokine‐activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin‐2

Mark R. Albertini, Jeffrey A. Sosman, Jacquelyn A. Hank, Karen H. Moore, Agnes Borchert, Kathleen Schell, Peter C. Kohler, Robin Bechhofer, Barry Storer, Paul M. Sondel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Twenty patients with refractory malignancies were treated with a protocol evaluating the addition of ex vivo‐activated autologous lymphokine‐activated killer (LAK) cells to a clinically tolerable interleukin‐2 (IL‐2) regimen (four weekly cycles of human recombinant IL‐2 at 3 × 106 U/m2/day by continuous infusion for 4 days/week). Sixteen patients completed their induction month of therapy, two had a partial response, six had stable disease, and eight had progressive disease. Four patients had clinical toxicity preventing completion of the induction month of therapy, and one of these patients died during therapy. Significant clinical toxities included decreased performance status, weight gain, catheter‐related thromboses, infectious complications, fever, hypotension, and dyspnea or hypoxemia requiring oxygen. Thus, the addition of LAK cell infusions to this IL‐2 regimen did not cause a noticeable change in antitumor response rate but did cause more severe toxicity.

Original languageEnglish (US)
Pages (from-to)2457-2464
Number of pages8
JournalCancer
Volume66
Issue number12
DOIs
StatePublished - Dec 15 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'the influence of autologous lymphokine‐activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin‐2'. Together they form a unique fingerprint.

Cite this